Serina Therapeutics Inc. (SER)
NYSE: SER
· Real-Time Price · USD
5.14
-0.14 (-2.65%)
At close: Sep 05, 2025, 10:03 AM
-2.65% (1D)
| Bid | 4.92 |
| Market Cap | 52.69M |
| Revenue (ttm) | 130K |
| Net Income (ttm) | -12.59M |
| EPS (ttm) | -0.92 |
| PE Ratio (ttm) | -5.59 |
| Forward PE | -2.95 |
| Analyst | Buy |
| Ask | 5.3 |
| Volume | 7,018 |
| Avg. Volume (20D) | 122,808 |
| Open | 5.12 |
| Previous Close | 5.28 |
| Day's Range | 5.11 - 5.34 |
| 52-Week Range | 3.81 - 10.28 |
| Beta | 0.76 |
Analyst Forecast
According to 0 analyst ratings, the average rating for SER stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-0.18%
Serina Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+2.91%
Serina Therapeutics shares are trading higher on possible continued strength after HC Wainwright & Co. initiated coverage on the stock yesterday with a Buy rating and announced a price target of $15.
1 month ago · seekingalpha.com
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughSeres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce ...